Journal Article Review Research Support, Non-U.S. Gov't Epublish 17 citations
PubMed: 36611926 DOI: 10.3390/cells12010132
Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cells 12(1)
Authors: Xiurong Cai, Adrien Guillot, Hanyang Liu
Affiliations
- Department of Hematology, Oncology and Tumor Immunology (CVK), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
- Department of Hepatology and Gastroenterology (CVK), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
- Department of Hepatology and Gastroenterology (CVK), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany. Center of Gastrointestinal Diseases, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Nanjing 213000, China.
Abstract
With the high morbidity and mortality, hepatocellular carcinoma (HCC) represents a major yet growing burden for our global community. The relapse-prone nature and drug resistance of HCC are regarded as the consequence of varying intracellular processes and extracellular interplay, which actively participate in tumor microenvironment remodeling. Amongst them, cellular senescence is regarded as a fail-safe program, leading to double-sword effects of both cell growth inhibition and tissue repair promotion. Particularly, cellular senescence serves a pivotal role in the progression of chronic inflammatory liver diseases, ultimately leading to carcinogenesis. Given the current challenges in improving the clinical management and outcome of HCC, senescence may exert striking potential in affecting anti-cancer strategies. In recent years, an increasing number of studies have emerged to investigate senescence-associated hepatocarcinogenesis and its derived therapies. In this review, we intend to provide an up-to-date understanding of liver cell senescence and its impacts on treatment modalities of HCC.
MeSH
Cells, Carcinoma, Hepatocellular, Neoplasms, Cellular Senescence, Liver, Liver Neoplasms, Carcinogenesis, Therapeutics
Cited by
- Identification of CCNB1 as a biomarker for cellular senescence in hepatocellular carcinoma: a bioinformatics and experimental validation study. Discov Oncol, 2025
- Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation. Cancer Med, 2025
- SASP Modulation for Cellular Rejuvenation and Tissue Homeostasis: Therapeutic Strategies and Molecular Insights. Cells, 2025
- Fibroblast atlas: Shared and specific cell types across tissues. Sci Adv, 2025
- Cellular Aging and Senescence in Cancer: A Holistic Review of Cellular Fate Determinants. Aging Dis, 2025
- Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. Cancer Immunol Immunother, 2025
- Sorafenib and Treg Differentiation: A Paradigm Shift in Hepatocellular Carcinoma Management. Cell Mol Gastroenterol Hepatol, 2025
- The Combination of Sorafenib and PGV-1 Inhibits the Proliferation of Hepatocellular Carcinoma Through c-Myc Suppression in an Additive Manner: In Vitro Studies. Adv Pharmacol Pharm Sci, 2024
- Cellular Senescence in Hepatocellular Carcinoma: Immune Microenvironment Insights via Machine Learning and In Vitro Experiments. Int J Mol Sci, 2025